For savvy investors looking for long-term businesses that not only dominate their industries today but also have the ...

Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...